Publication:
A potential novel treatment strategy: inhibition of angiogenesis and inflammation by resveratrol for regression of endometriosis in an experimental rat model

dc.contributor.authorCenksoy, PINAR
dc.contributor.authorÖKTEM, MESUT
dc.contributor.authorERDEM, ÖZLEM
dc.contributor.authorKarakaya, Cengiz
dc.contributor.authorCenksoy, Cahit
dc.contributor.authorERDEM, AHMET
dc.contributor.authorGuner, Haldun
dc.contributor.authorKARABACAK, RECEP ONUR
dc.contributor.institutionauthorÖZCAN, PINAR
dc.date.accessioned2020-12-16T20:59:20Z
dc.date.available2020-12-16T20:59:20Z
dc.date.issued2015-03-01T00:00:00Z
dc.description.abstractThe aim of our study was to evaluate the effectiveness of resveratrol in experimentally induced endometrial implants in rats through inhibiting angiogenesis and inflammation. Endometrial implants were surgically induced in 24 female Wistar Albino rats in the first surgery. After confirmation of endometriotic foci in the second surgery, the rats were divided into resveratrol (seven rats), leuprolide acetate (eight rats), and control (seven rats) groups and medicated for 21 d. In the third surgery, the measurements of mean areas and histopathological analysis of endometriotic lesions, VEGF, and MCP-1 measurements in blood and peritoneal fluid samples, and immunohistochemical staining were evaluated. After treatment, significant reductions in mean areas of implants (p < 0.01) and decreased mean histopathological scores of the implants (p < 0.05), mean VEGF-staining scores of endometriotic implants (p = 0.01), and peritoneal fluid levels of VEGF and MCP-1 (p < 0.01, for VEGF and p < 0.01, for MCP-1) were found in the resveratrol and leuprolide acetate groups. Serum VEGF (p = 0.05) and MCP-1 (p = 0.01) levels after treatment were also significantly lower in the resveratrol and leuprolide acetate groups. Resveratrol appears to be a potential novel therapeutic agent in the treatment of endometriosis through inhibiting angiogenesis and inflammation. Further studies are needed to determine the optimum effective dose in humans and to evaluate other effects on reproductive physiology.
dc.identifier.citationCenksoy P., ÖKTEM M., ERDEM Ö., Karakaya C., Cenksoy C., ERDEM A., Guner H., KARABACAK R. O. , -A potential novel treatment strategy: inhibition of angiogenesis and inflammation by resveratrol for regression of endometriosis in an experimental rat model-, GYNECOLOGICAL ENDOCRINOLOGY, cilt.31, ss.219-224, 2015
dc.identifier.doi10.3109/09513590.2014.976197
dc.identifier.scopus84931411349
dc.identifier.urihttp://hdl.handle.net/20.500.12645/27709
dc.identifier.wosWOS:000358467100010
dc.titleA potential novel treatment strategy: inhibition of angiogenesis and inflammation by resveratrol for regression of endometriosis in an experimental rat model
dc.typeArticle
dspace.entity.typePublication
local.avesis.id6f3a96f0-c345-403d-9fdc-96d0f0f0eba3
local.publication.isinternational1
relation.isAuthorOfPublicationa223be34-acbb-4ec3-8217-209ec916f373
relation.isAuthorOfPublication.latestForDiscoverya223be34-acbb-4ec3-8217-209ec916f373
Files
Collections